
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX is a company with a promising future, as evidenced by their high sensitivity and specificity rates for cancer detection using their breakthrough Capture-Seq technology. With a potential application for multi-cancer early detection and treatment monitoring, VolitionRX could see significant market traction and valuation in the future. Along with positive clinical data and potential partnerships, VolitionRX's financials also look promising with a current market value of $190M and a DCF-based asset value of $201M for Nu.Q diagnostic tests. However, risks such as failure in clinical development, difficulties securing license agreements, and dilution risk should be considered when evaluating the company.
Bears say
VolitionRX is a company with a number of potential risks, including Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk. While the company has made some progress in terms of platform validation and securing partnerships, the recent reverse split and continued need for additional funding suggest that turning this progress into sustainable commercial success may prove challenging. Additionally, VolitionRX's financials are a cause for concern, with a low cash balance and consistent losses, factors that may make investors cautious.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares